Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines

NCT03736928 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT03736928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03736928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
Lead sponsor
Galderma R&D
Phase
Phase 2
Overall status
Completed
Start date
November 26, 2018
Completion date
August 20, 2020
Enrollment
401 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines